The stock of Capricor Therapeutics Inc (CAPR) has gone up by 16.19% for the week, with a -20.80% drop in the past month and a 22.77% rise in the past quarter. The volatility ratio for the week is 5.23%, and the volatility levels for the past 30 days are 14.81% for CAPR. The simple moving average for the last 20 days is 3.84% for CAPR stock, with a simple moving average of -17.77% for the last 200 days.
Is It Worth Investing in Capricor Therapeutics Inc (NASDAQ: CAPR) Right Now?
The stock has a 36-month beta value of 0.61. Opinions on the stock are mixed, with 7 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CAPR is 40.15M, and at present, short sellers hold a 25.44% of that float. On July 09, 2025, the average trading volume of CAPR was 2.60M shares.
CAPR) stock’s latest price update
Capricor Therapeutics Inc (NASDAQ: CAPR) has seen a rise in its stock price by 10.82% in relation to its previous close of $10.17. However, the company has experienced a 16.19% gain in its stock price over the last five trading sessions. prnewswire.com reported 2025-07-07 that NEW YORK, July 7, 2025 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Analysts’ Opinion of CAPR
Many brokerage firms have already submitted their reports for CAPR stocks, with Alliance Global Partners repeating the rating for CAPR by listing it as a “Buy.” The predicted price for CAPR in the upcoming period, according to Alliance Global Partners is $20 based on the research report published on June 30, 2025 of the current year 2025.
B. Riley Securities, on the other hand, stated in their research note that they expect to see CAPR reach a price target of $21. The rating they have provided for CAPR stocks is “Buy” according to the report published on June 26th, 2025.
Roth Capital gave a rating of “Buy” to CAPR, setting the target price at $31 in the report published on May 20th of the current year.
CAPR Trading at 6.75% from the 50-Day Moving Average
After a stumble in the market that brought CAPR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.84% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CAPR starting from Nippon Shinyaku Co Ltd, who purchase 2,798,507 shares at the price of $5.36 back on Sep 20 ’24. After this action, Nippon Shinyaku Co Ltd now owns 7,090,351 shares of Capricor Therapeutics Inc, valued at $14,999,998 using the latest closing price.
Stock Fundamentals for CAPR
Current profitability levels for the company are sitting at:
- -3.3 for the present operating margin
- 1.0 for the gross margin
The net margin for Capricor Therapeutics Inc stands at -3.17. The total capital return value is set at -0.44. Equity return is now at value -75.39, with -54.19 for asset returns.
Based on Capricor Therapeutics Inc (CAPR), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -36.14.
Currently, EBITDA for the company is -41.14 million with net debt to EBITDA at 0.49. When we switch over and look at the enterprise to sales, we see a ratio of 28.37. The receivables turnover for the company is 290.2for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.55.
Conclusion
To sum up, Capricor Therapeutics Inc (CAPR) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
